Patent Oppositions in immune drugs industry

Explore the competitive field of immune drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in immune drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the immune drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the immune drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Oct 29, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Mucosal-Associated Invariant T (Mait) Cells Expressing Chimeric Antigen ReceptorsINSTITUT CURIEOct 28, 2026GOODWIN PROCTER UK
Binding Molecules For Bcma And Cd3AMGENOct 6, 2026STRAWMAN
Compositions And Methods Of Treating Lupus NephritisF HOFFMANN LA ROCHESep 30, 2026KERNEBECK PATENTANWALTS
Compositions And Methods Of Treating Lupus NephritisF HOFFMANN LA ROCHESep 30, 2026KERNEBECK PATENTANWALTS
Compositions And Methods Of Treating Lupus NephritisF HOFFMANN LA ROCHESep 29, 2026WUESTHOFF & WUESTHOFF
Compositions And Methods Of Treating Lupus NephritisF HOFFMANN LA ROCHESep 29, 2026WUESTHOFF & WUESTHOFF
Methods Of Treating Crohn'S Disease With Anti-Il23 Specific AntibodyJANSSEN BIOTECHSep 24, 2026SANDOZ
Dosage Forms For Tyk2 InhibitorsBRISTOL MYERS SQUIBBSep 24, 2026KERNEBECK PATENTANWALTS
Methods Of Treating Crohn'S Disease With Anti-Il23 Specific AntibodyJANSSEN BIOTECHSep 23, 2026POLPHARMA BIOLOGICS
Dosage Forms For Tyk2 InhibitorsBRISTOL MYERS SQUIBBSep 23, 2026SANDOZ

To stay ahead in the competitive immune drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the immune drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Oct 29, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS24
Nov 2, 2016Multiple-Variable Dose Regimen For Treating Tnfalpha-Related DisordersABBVIE BIOTECHNOLOGY11
Jan 18, 2017Methods Of Administering Anti-Tnfalpha AntibodiesABBVIE BIOTECHNOLOGY11
Dec 13, 2023Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv InfectionVIIV HEALTHCARE10
Jul 3, 2019Pharmaceutical Compositions Comprising An S1P ModulatorNOVARTIS8
Dec 24, 2025Methods Of Treating Crohn'S Disease With Anti-Il23 Specific AntibodyJANSSEN BIOTECH8
Sep 11, 2019Binding Molecules For Bcma And Cd3BOEHRINGER INGELHEIM8
Dec 3, 2025Safe And Effective Method Of Treating Psoriasis With Anti-Il23 Specific AntibodyJANSSEN BIOTECH8
Mar 3, 2021Tofacitinib Oral Sustained Release Dosage FormsPFIZER7
Aug 21, 2019Binding Molecules For Bcma And Cd3AMGEN7